Related Experiment Videos
Statins
1Heart and Vascular Program, St Michael's Hospital, Leslie L Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC
|March 1, 2003
Summary
Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors, or statins, are common lipid-lowering drugs. Risk stratification can identify women who would benefit from statins for cardiovascular disease prevention, despite contraindications in pregnancy.
Area of Science:
- Cardiovascular medicine
- Pharmacology
Background:
- Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors, known as statins, are widely prescribed lipid-lowering medications.
- These drugs are contraindicated in pregnant women and those planning conception.
- However, many individuals, including women, could benefit from statin therapy.
Purpose of the Study:
- To highlight the benefits of statins in cardiovascular disease prevention.
- To emphasize the need for risk stratification in identifying suitable candidates for statin therapy, particularly women.
Main Methods:
- Review of multiple randomized controlled trials on statin efficacy.
- Analysis of risk stratification tools for identifying women who would benefit from statins.
Main Results:
- Statins are proven effective in primary and secondary prevention of coronary artery disease.
- Risk stratification tools can successfully identify women who would benefit from these medications.
Conclusions:
- Statins offer significant benefits for coronary artery disease prevention.
- Appropriate risk stratification is crucial for identifying women who can safely benefit from statins, despite contraindications during pregnancy.